Aligos Therapeutics has a one year low of $6.76 and a one year high of $46.80. The stock has a market capitalization of $43.65 million, a price-to-earnings ratio of -0.54 and a beta of 2.52.

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel ...

16:07 EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holders Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed ...

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 60.4% of Aligos Therapeutics shares are held by institutional investors.

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical ...

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS,“Aligos”,“Company ...